Results 231 to 240 of about 16,747 (255)
Some of the next articles are maybe not open access.
Micafungin - The newest echinocandin
Drugs of Today, 2009Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it
Zelalem Temesgen +2 more
openaire +3 more sources
Update on Echinocandin Antifungals
Seminars in Respiratory and Critical Care Medicine, 2008Echinocandins are semisynthetic lipopeptides that competitively inhibit an essential cell wall component of Candida and aspergillus. They are generally inactive against other fungi. Resistance to these agents is infrequent to date. Echinocandins exhibit low oral bioavailability and are available only as parenteral formulations that are dosed once daily.
Peggy L. Carver, Carol A. Kauffman
openaire +3 more sources
The first echinocandin: caspofungin
Mycoses, 2002Summary. The antifungal agent caspofungin is the first echinocandin that has been approved in the US and in Europe for treatment of invasive aspergillosis in adult patients who are refractory to or intolerant of conventional amphotericin B, its lipid‐based formulations, and/or itraconazole.
Karina Schmitz +2 more
openaire +3 more sources
The Lancet, 2003
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +4 more sources
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +4 more sources
Echinocandins for the Nursery: An Update
Current Drug Metabolism, 2013As the incidence rates of neonatal invasive fungal infection (IFI) have been increasing over the last years, research efforts have been addressed towards identifying both effective preventative strategies, and efficacious and well-tolerated antifungal drugs.
Michael Cohen-Wolkowiez +7 more
openaire +3 more sources
Echinocandins: Are They All The Same?
Journal of Chemotherapy, 2011The discovery of echinocandins, and their development and approval, was hailed as a significant addition to our antifungal armamentarium, previously predominated by polyenes and azoles. To date, three echinocandins (anidulafungin, caspofungin, and micafungin) have been approved by the U.S.
Mahmoud A. Ghannoum +4 more
openaire +3 more sources
Expert Opinion on Therapeutic Patents, 2002
Echinocandins and echinocandin-like compounds are non-competitive inhibitors of the synthesis of 1,3-β-D-glucan, a major and essential component in the wall of many important fungal pathogens. Since this polysaccharide is not present in mammalian cells the glucan synthase became an attractive target for the development of new antifungal agents.
openaire +2 more sources
Echinocandins and echinocandin-like compounds are non-competitive inhibitors of the synthesis of 1,3-β-D-glucan, a major and essential component in the wall of many important fungal pathogens. Since this polysaccharide is not present in mammalian cells the glucan synthase became an attractive target for the development of new antifungal agents.
openaire +2 more sources
Pharmacokinetics/pharmacodynamics of echinocandins
European Journal of Clinical Microbiology & Infectious Diseases, 2004The novel class of echinocandins represents a milestone in antifungal drug research that has further expanded our therapeutic options. The favorable pharmacokinetic profile of the echinocandins has been elucidated in animal and human studies. The echinocandins are targeted for once-daily dosing and are not metabolized through the cytochrome P450 enzyme
openaire +3 more sources
Tetrahedron Letters, 1992
Abstract Sodium cyanoborohydride in trifluoroacetic acid selectively reduced the C5-orn and C4-htyr carbinols to methylene groups in echinocandin lipopeptides. The selective reduction of either hydroxyl is also described. The first conversion of echinocandin B to echinocandin C was accomplished.
James M. Balkovec, Black Regina M
openaire +2 more sources
Abstract Sodium cyanoborohydride in trifluoroacetic acid selectively reduced the C5-orn and C4-htyr carbinols to methylene groups in echinocandin lipopeptides. The selective reduction of either hydroxyl is also described. The first conversion of echinocandin B to echinocandin C was accomplished.
James M. Balkovec, Black Regina M
openaire +2 more sources
Echinocandins: The Newest Class of Antifungals
Annals of Pharmacotherapy, 2009Objective: To review the mechanism of action, antifungal spectrum of activity, pharmacodynamics, pharmacokinetics, clinical efficacy, and safety of the echinocandins. Data Sources: A MEDLINE search (1982–May 2009) was conducted for articles published in the English language using the key words caspofungin, micafungin, anidulafungin, and echinocandins ...
Sucher, Allana J. +2 more
openaire +3 more sources